Protara Therapeutics (TARA) Retained Earnings (2013 - 2026)

Protara Therapeutics (TARA) has 14 years of Retained Earnings data on file, last reported at $501.7 million in Q1 2026.

• On a quarterly basis, Retained Earnings rose 20.82% year-over-year to $501.7 million in Q1 2026; TTM through Mar 2026 was $501.7 million, a 20.82% increase from a year earlier, with the FY2025 full-year figure at $90000.0, down 99.98% from the prior year.
• Retained Earnings for Q1 2026 stood at $501.7 million, up from $90000.0 in the prior quarter.
• Over the last five years, Retained Earnings for TARA reached as high as $501.7 million in Q1 2026 and fell as low as -$285.1 million in Q3 2025.
• Historically, Retained Earnings has averaged $60.2 million across 5 years, with a median of -$165000.0 in 2023.
• Across the five-year window, Retained Earnings plunged 63782.32% in 2022 and soared 190373.94% in 2024, its largest moves.
• Year by year, Retained Earnings stood at -$160.0 million in 2022, then dropped by 25.27% to -$200.4 million in 2023, then soared by 305.64% to $412.1 million in 2024, then sank by 99.98% to $90000.0 in 2025, then soared by 557364.44% to $501.7 million in 2026.
• Per Business Quant data, the three most recent Retained Earnings figures were $501.7 million in Q1 2026, $90000.0 in Q4 2025, and -$285.1 million in Q3 2025.